Bachground An upper arm brachiobasic arteriovenous fistula (BBAVF) is a dependable, autogenous, one-stage or two-stage access to a hemodialysis system. Each technique has benefits and cons, according to past research. In this research, the difference between one and two phases of brachio-basic arteriovenous fistula was rigorously evaluated for access ripening, patency, postoperative problems and patient type appropriate for each treatment. Methods: Methods This research comprised 50 regularly split patients with end stage renal disease (ESRD) in Group A, 25 of whom had one stage brachio-basic arteriovenous fistula (BBAVF) and Group B, 25 of whom had two stage BBAVF patients. Results: The diameter of the target vein was statistically considerably bigger than that of group B. A statistically significant difference between the two groups was not shown by the main failure rate. The period of primary functional patenting, primary function patenting and secondary functional patenting in days in group B were substantially longer. In group B the proportion of primary functional patentability, primary functional patentability and secondary functional patentability in days were much longer. The incidence of complications between the cases in both groups was not statistically significantly different. Age, DM, HTN and vein diameter reduction <3mm were linked with factors for failure of BBAVF. Conclusion: before using prothetic grafts Brachiobasilic fistulas should be examined. Their development using a two-stage approach should lead to better patenting rates along with other advantageschnical advantages.